DNM1L and neoplasm: But patients with RAGE-G82S polymorphism displayed high phospho-Drp1 Ser616 after neoCRT treatment (p = 0.05, Table 3), suggesting that patients with RAGE-G82S polymorphisms may have increased Drp1 activation to promote chemoresistance and tumor regrowth after chemoradiotherapy treatment, leading to poor survival outcome in LARC.